ROCKVILLE, Md., Feb. 21 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Maxine Gowen, Ph.D., President and Chief Executive Officer of Trevena, Inc., a privately held drug discovery company, has been appointed to the HGS Board of Directors. Prior to joining Trevena, Dr. Gowen spent 15 years at GlaxoSmithKline (GSK), where she held a series of executive management positions in drug discovery and development, and led the GSK venture capital subsidiary, S.R. One.
"Maxine Gowen brings significant leadership experience to HGS in drug discovery, biotechnology venture capital investing, and business development," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "She has a distinguished record of accomplishment, and we are honored to have her join our Board of Directors. We look forward to benefiting from Maxine's experience and insight in the years ahead."
Trevena, which Dr. Gowen currently heads, is based in Berwyn,
Pennsylvania, and is focused on the discovery and development of novel
agents that target G-protein coupled receptors, a family of cell surface
receptors with many functions, including immune responses and the
regulation of cellular growth and reproduction. Prior to joining Trevena,
Dr. Gowen was Senior Vice President of GSK's Center of Excellence for
External Drug Discovery. In that position, Dr. Gowen built and led a new
R&D division with a mission to create a drug discovery portfolio through
business development alliances with innovative healthcare companies. She
joined GSK in 1992 to lead the Musculoskeletal
|SOURCE Human Genome Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved